These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 34487230)

  • 1. Indolent T cell lymphoma involving the central nervous system and successfully treated by bendamustine.
    Hui M; Chen M
    Ann Hematol; 2022 Apr; 101(4):911-913. PubMed ID: 34487230
    [No Abstract]   [Full Text] [Related]  

  • 2. Bendamustine in indolent non-Hodgkin's lymphoma: a practice guide for patient management.
    Brugger W; Ghielmini M
    Oncologist; 2013; 18(8):954-64. PubMed ID: 23900001
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Bendamustine plus rituximab as first-line treatment in patients with indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma : a real-world study in China].
    Du KX; Shen HR; Wang L; Liang JH; Wu JZ; Li Y; Xia Y; Yin H; Li JY; Xu W
    Zhonghua Xue Ye Xue Za Zhi; 2023 Apr; 44(4):333-336. PubMed ID: 37357004
    [No Abstract]   [Full Text] [Related]  

  • 4. The discovery and the development of bendamustine for the treatment of non-Hodgkin lymphoma.
    Munakata W; Tobinai K
    Expert Opin Drug Discov; 2016 Nov; 11(11):1123-1130. PubMed ID: 27598460
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bendamustine: a review of its use in the management of indolent non-Hodgkin's lymphoma and mantle cell lymphoma.
    Garnock-Jones KP
    Drugs; 2010 Sep; 70(13):1703-18. PubMed ID: 20731477
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bendamustine-rituximab in mantle cell lymphoma.
    Lipsky A; Martin P
    Lancet Haematol; 2017 Jan; 4(1):e2-e3. PubMed ID: 27927585
    [No Abstract]   [Full Text] [Related]  

  • 7. The combination of bendamustine, bortezomib, and rituximab for patients with relapsed/refractory indolent and mantle cell non-Hodgkin lymphoma.
    Friedberg JW; Vose JM; Kelly JL; Young F; Bernstein SH; Peterson D; Rich L; Blumel S; Proia NK; Liesveld J; Fisher RI; Armitage JO; Grant S; Leonard JP
    Blood; 2011 Mar; 117(10):2807-12. PubMed ID: 21239695
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An evaluation of the potential for drug-drug interactions between bendamustine and rituximab in indolent non-Hodgkin lymphoma and mantle cell lymphoma.
    Darwish M; Burke JM; Hellriegel E; Robertson P; Phillips L; Ludwig E; Munteanu MC; Bond M
    Cancer Chemother Pharmacol; 2014 Jun; 73(6):1119-27. PubMed ID: 24677018
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differences in Quality of Life Between Bendamustine-Rituximab and R-CHOP/R-CVP in Patients With Previously Untreated Advanced Indolent Non-Hodgkin Lymphoma or Mantle Cell Lymphoma.
    Burke JM; van der Jagt RH; Kahl BS; Wood P; Hawkins TE; MacDonald D; Hertzberg M; Simpson D; Craig M; Kolibaba K; Issa S; Munteanu M; Victor TW; Flinn IW
    Clin Lymphoma Myeloma Leuk; 2016 Apr; 16(4):182-190.e1. PubMed ID: 26875824
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High anti-lymphoma activity of bendamustine/mitoxantrone/rituximab in rituximab pretreated relapsed or refractory indolent lymphomas and mantle cell lymphomas. A multicenter phase II study of the German Low Grade Lymphoma Study Group (GLSG).
    Weide R; Hess G; Köppler H; Heymanns J; Thomalla J; Aldaoud A; Losem C; Schmitz S; Haak U; Huber C; Unterhalt M; Hiddemann W; Dreyling M;
    Leuk Lymphoma; 2007 Jul; 48(7):1299-306. PubMed ID: 17613757
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bendamustine: a review of its use in the management of indolent non-Hodgkin lymphoma.
    Plosker GL; Carter NJ
    Drugs; 2008; 68(18):2645-60. PubMed ID: 19093705
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HBV reactivation in malignant lymphoma patients treated with rituximab and bendamustine.
    Tsutsumi Y; Ogasawara R; Miyashita N; Tanaka J; Asaka M; Imamura M
    Int J Hematol; 2012 May; 95(5):588-91. PubMed ID: 22419099
    [No Abstract]   [Full Text] [Related]  

  • 13. Bendamustine in the treatment of non-Hodgkin's lymphoma: results and future perspectives.
    Rummel MJ; Mitrou PS; Hoelzer D
    Semin Oncol; 2002 Aug; 29(4 Suppl 13):27-32. PubMed ID: 12170430
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetic profile and first preliminary clinical evaluation of bendamustine in Taiwanese patients with heavily pretreated indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma.
    Hsiao LT; Tien HF; Kuo CY; Wu JH; Hou HA; Wang MC; Liu CY; Chen PM; Chiou TJ
    Hematol Oncol; 2015 Dec; 33(4):136-44. PubMed ID: 25111959
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bendamustine in lymphomas: more to combine?
    Bertoni F; Zucca E
    Leuk Lymphoma; 2007 Jul; 48(7):1264-6. PubMed ID: 17613752
    [No Abstract]   [Full Text] [Related]  

  • 16. Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study.
    Flinn IW; van der Jagt R; Kahl BS; Wood P; Hawkins TE; Macdonald D; Hertzberg M; Kwan YL; Simpson D; Craig M; Kolibaba K; Issa S; Clementi R; Hallman DM; Munteanu M; Chen L; Burke JM
    Blood; 2014 May; 123(19):2944-52. PubMed ID: 24591201
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bendamustine-based therapy as first-line treatment for non-Hodgkin lymphoma.
    Gil L; Kazmierczak M; Kroll-Balcerzak R; Komarnicki M
    Med Oncol; 2014 May; 31(5):944. PubMed ID: 24752517
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bendamustine, vincristine and prednisone (BOP) versus cyclophosphamide, vincristine and prednisone (COP) in advanced indolent non-Hodgkin's lymphoma and mantle cell lymphoma: results of a randomised phase III trial (OSHO# 19).
    Herold M; Schulze A; Niederwieser D; Franke A; Fricke HJ; Richter P; Freund M; Ismer B; Dachselt K; Boewer C; Schirmer V; Weniger J; Pasold R; Winkelmann C; Klinkenstein C; Schulze M; Arzberger H; Bremer K; Hahnfeld S; Schwarzer A; Müller C; Müller C;
    J Cancer Res Clin Oncol; 2006 Feb; 132(2):105-12. PubMed ID: 16088404
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of bendamustine in combination with rituximab on QT interval duration in patients with advanced de novo indolent non-Hodgkin or mantle cell lymphoma.
    Burke JM; van der Jagt RH; Flinn IW; Craig MD; Chen L; Morganroth J; Munteanu MC; MacDonald DA
    Cancer Chemother Pharmacol; 2015 Jul; 76(1):211-6. PubMed ID: 26006703
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Polatuzumab vedotin plus bendamustine and rituximab (Pola-BR) was effective for neurolymphomatosis in a patient with refractory diffuse large B-cell lymphoma.
    Shinmura K; Okubo S; Kadota S; Nakayama H; Sakurai A; Kurosawa S; Ito C; Aisa Y; Nakazato T
    Ann Hematol; 2023 Jan; 102(1):223-225. PubMed ID: 36394579
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.